canakinumab   

GtoPdb Ligand ID: 6773

Synonyms: ACZ 885 | ACZ885 | Ilaris®
canakinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Canakinumab targets interleukin-1β [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
No information available.
Summary of Clinical Use
Used to treat rheumatic diseases; familial cold autoinflammatory syndrome (FCAS) [4] and Muckle-Wells syndrome (MWS) in patients >4 years of age, and systemic juvenile idiopathic arthritis (sJIA) in patients >2 years old [7].
Mechanism Of Action and Pharmacodynamic Effects
A monoclonal antibody which binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors [1], but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). The patent claiming this antibody, US7446175, reports that the antigenic epitope on IL-1β is the loop containing the Glu64 residue in the mature cytokine (equivalent to residue 180 of the precursor peptide) [3]
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01327846 Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) Phase 3 Interventional Novartis Results from the CANTOS trial (NCT01327846) showed that canakinumab (in high-risk patients; in addition to standard-of-care therapy) reduced the number of recurrent cardiovascular events that were recorded at 3-4 years follow-up 2
External links